FDA approves mAb combo for hepatocellular carcinomaJune 1, 2020GastroenterologyGastrointestinal Cancer
Treating primary tumor doesn’t improve OS in stage IV breast cancerJune 1, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphomaJune 1, 2020Lymphoma & Plasma Cell Disorders
Pyrotinib bests lapatinib in HER2+ metastatic breast cancerMay 31, 2020Breast CancerMetastatic Breast CancerASCO Breast Cancer
Expanding the role of PARP inhibitors in breast cancerMay 31, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancerMay 31, 2020Breast CancerASCO Breast Cancer
Short-course radiotherapy and chemo may reduce treatment failures in high-risk rectal cancerMay 30, 2020GastroenterologyGastrointestinal Cancer
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastasesMay 30, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancerMay 30, 2020Breast CancerASCO Breast Cancer
